Budesonide

BreastfeedingPediatric
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Boceprevir, Efavirenz, Itraconazole, Ketoconazole, Live vaccines, Oral Contraceptives, Telaprevir

PREGNANCY CATEGORY: C

Under investigation for treating COVID-19

See adverse reactions attributed to class:

Corticosteroid / Glucocorticoid

Corticosteroid, inhaled

Symbicort is budesonide and formoterol.

Acneiform eruption / acneiform dermatitis / acneiform rash 

(2018): Bezzio C+, Expert Opin Drug Saf 17(4), 437 [REVIEW]<1% (MMX formulation)

(2014): Kuenzig ME+, Cochrane Database Syst Rev 8, CD002913 [REVIEW]

(2010): Thacker D+, Ann Thorac Surg 89 (3), 837

Angioedema 

(2003): Pirker C+, Contact Dermatitis 49(2), 77-9

Cushingoid features 

(2010): Thacker D+, Ann Thorac Surg 89 (3), 837

Dermatitis 

(2011): Henningsen E+, Pediatr Dermatol 28(5), 596

(2009): Uter W+, J Dtsch Dermatol Ges 7(1), 34

(1997): Vestergaard L+, Ugeskr Laeger (Danish) 159, 5662

(1993): Hisa T+, Contact Dermatitis 28, 174

(1993): Noda H+, Contact Dermatitis 28(4), 212 (5 cases)

(1991): Dunkel FG+, Contact Dermatitis 25(2), 97-1 [REVIEW] (2 cases)

(1991): Gamboa PM+, Contact Dermatitis 24(3), 227

(1991): Piraccini BM+, Contact Dermatitis 24(1), 54-5

Edema / fluid retention (see also peripheral edema) 

(2018): Bezzio C+, Expert Opin Drug Saf 17(4), 437 [REVIEW]1% (MMX formulation)

Edema of lip 

(2003): Pirker C+, Contact Dermatitis 49(2), 77-9

Exanthems 

(2016): Sharma PK+, J Clin Diagn Res 10(10), FD01

(2000): Bircher AJ+, Dermatology 200(4), 349

Flushing / rubefaction 

(2018): Bezzio C+, Expert Opin Drug Saf 17(4), 437 [REVIEW]<1% (MMX formulation)

Hypersensitivity 

(2016): Sharma PK+, J Clin Diagn Res 10(10), FD01

Moon face 

(2018): Bezzio C+, Expert Opin Drug Saf 17(4), 437 [REVIEW]<2% (MMX formulation)

(2014): Kuenzig ME+, Cochrane Database Syst Rev 8, CD002913 [REVIEW]

Pruritus (itching) 

(2016): Sharma PK+, J Clin Diagn Res 10(10), FD01

(2003): Pirker C+, Contact Dermatitis 49(2), 77-9

Rash 

(2003): Kilpio K+, Allergy 58(11), 1131

(1993): Hisa T+, Contact Dermatitis 28(3), 174

Skin toxicity / toxicity 

(2016): Badiu R+, Clujul Med 89(2), 273 (with atorvastatin)

Striae 

(2014): Kuenzig ME+, Cochrane Database Syst Rev 8, CD002913 [REVIEW]

Alopecia / hair loss 

(2014): Kuenzig ME+, Cochrane Database Syst Rev 8, CD002913 [REVIEW]

Hirsutism 

(2014): Kuenzig ME+, Cochrane Database Syst Rev 8, CD002913 [REVIEW]

Cheilitis 

(2017): Zadik Y+, Expert Opin Pharmacother 18(3), 235

Nasal dryness 

(2015): Wang C+, J Allergy Clin Immunol 135(4), 922 (5 cases)

Oral candidiasis 

(2017): Zadik Y+, Expert Opin Pharmacother 18(3), 235

(1984): Clissold SP+, Drugs 28, 485 [REVIEW]

Dysrhythmia 

(2014): Iftikhar IH+, Lung 192(1), 47 [REVIEW] (with formoterol)

Delirium 

(2014): Moss JM+, J Pharm Pract 27(1), 79 (with formoterol)

Dysgeusia (taste perversion) 

(2017): Zadik Y+, Expert Opin Pharmacother 18(3), 235

Fever (pyrexia) 

(2018): Bezzio C+, Expert Opin Drug Saf 17(4), 437 [REVIEW]<2% (MMX formulation)

(2014): Aagaard L+, Int J Clin Pharm 36(2), 243 [REVIEW]Pediatric (with formoterol)

Headache 

(2018): Bezzio C+, Expert Opin Drug Saf 17(4), 437 [REVIEW]6–15% (MMX formulation)

(2014): Aagaard L+, Int J Clin Pharm 36(2), 243 [REVIEW]Pediatric (with formoterol)

Insomnia 

(2018): Bezzio C+, Expert Opin Drug Saf 17(4), 437 [REVIEW]<2% (MMX formulation)

(2014): Kuenzig ME+, Cochrane Database Syst Rev 8, CD002913 [REVIEW]

Mood changes 

(2018): Bezzio C+, Expert Opin Drug Saf 17(4), 437 [REVIEW]2–4% (MMX formulation)

(2014): Kuenzig ME+, Cochrane Database Syst Rev 8, CD002913 [REVIEW]

Panic attack 

(2018): Ruihong Z+, Pak J Pharm Sci 31(5(Special)), 2249 (2 cases) (with terbutaline)

Sleep-related disorder 

(2018): Bezzio C+, Expert Opin Drug Saf 17(4), 437 [REVIEW]2% (MMX formulation)

Adrenal insufficiency 

(2017): Manji J+, Int Forum Allergy Rhinol 7(5), 4883%

(2012): Yoganathan K+, Int J STD AIDS 23(7), 520 (with ritonavir interaction)

(2002): Skov M+, Eur Respir J 20(1), 127 (with itraconazole)

Cushing's syndrome 

(2017): Tripathi K+, ACG Case Rep J 4, e5

(2012): Yoganathan K+, Int J STD AIDS 23(7), 520 (with ritonavir interaction)

Hypokalemia 

(2018): Bezzio C+, Expert Opin Drug Saf 17(4), 437 [REVIEW]<1% (MMX formulation)

Weight gain 

(2014): Kuenzig ME+, Cochrane Database Syst Rev 8, CD002913 [REVIEW]

Abdominal pain 

(2018): Bezzio C+, Expert Opin Drug Saf 17(4), 437 [REVIEW]2–3% (MMX formulation)

Colitis 

(2018): Bezzio C+, Expert Opin Drug Saf 17(4), 437 [REVIEW]10–17% (MMX formulation)

Diarrhea 

(2018): Bezzio C+, Expert Opin Drug Saf 17(4), 437 [REVIEW]<2% (MMX formulation)

Dysphagia 

(2003): Pirker C+, Contact Dermatitis 49(2), 77-9

Flatulence 

(2018): Bezzio C+, Expert Opin Drug Saf 17(4), 437 [REVIEW]<3% (MMX formulation)

Gastrointestinal disorder / discomfort 

(2020): Fellermann K+, United European Gastroenterol J Oct, Online ahead of print16%

Nausea 

(2018): Bezzio C+, Expert Opin Drug Saf 17(4), 437 [REVIEW]3–5% (MMX formulation)

Back pain 

(2018): Bezzio C+, Expert Opin Drug Saf 17(4), 437 [REVIEW]<2% (MMX formulation)

Cataract 

(2011): Guner SN+, J Investig Allergol Clin Immunol 21(1), 80

(2009): Ozkiraz S+, J Matern Fetal Neonatal Med 22(4), 368

Eyelid edema 

(2003): Pirker C+, Contact Dermatitis 49(2), 77-9

Intraocular pressure increased 

(2017): Manji J+, Int Forum Allergy Rhinol 7(5), 4886%

Periorbital dermatitis 

(2011): Henningsen E+, Pediatr Dermatol 28(5), 596

Asthma 

(exacerbation)

(2017): Petrova G+, SAGE Open Med 5, Epub

(2015): Vogelmeier C+, Eur Respir J 45(5), 12738%

(2014): Aagaard L+, Int J Clin Pharm 36(2), 243 [REVIEW]Pediatric (exacerbation / with formoterol)

(2014): Antilla M+, J Bras Pneumol 40(6), 59917% (with formoterol)

Bronchitis 

(2019): Ichinose M+, Int J Chron Obstruct Pulmon Dis 14, 299310% (with glycopyrrolate and formoterol)

Cough 

(2014): Aagaard L+, Int J Clin Pharm 36(2), 243 [REVIEW]Pediatric (with formoterol)

(2003): Dubus JC+, Fundam Clin Pharmacol 17(5), 627

Nasopharyngitis 

(2019): Ichinose M+, Int J Chron Obstruct Pulmon Dis 14, 299332% (with glycopyrrolate and formoterol)

(2014): Antilla M+, J Bras Pneumol 40(6), 59922% (with formoterol)

Pharyngitis 

(2018): Ruihong Z+, Pak J Pharm Sci 31(5(Special)), 2249 (8 cases) (with terbutaline)

Pneumonia 

(2014): Kew KM+, Cochrane Database Syst Rev 3, CD010115 [REVIEW]

Rhinitis 

(2014): Antilla M+, J Bras Pneumol 40(6), 59917% (with formoterol)

Upper respiratory tract infection 

(2014): Aagaard L+, Int J Clin Pharm 36(2), 243 [REVIEW]Pediatric (with formoterol)

Adverse effects 

(2021): Omori T+, Expert Opin Pharmacother Apr, Online ahead of print4%

(2018): Dorinsky P+, Pulm Pharmacol Ther May, Epub ahead of print (with glycopyrrollate and formoterol)

(2018): Miehlke S+, Gastroenterology Sep, Epub ahead of print68%

(2016): Munch A+, Gut 65(1), 47 (7 cases)

(2015): Lichtenstein GR+, J Crohns Colitis 9(9), 7386–12%

(2015): Sun X+, Pulm Pharmacol Ther 31, 111

(2014): Aagaard L+, Int J Clin Pharm 36(6), 122221%

(2013): Marogna M+, Allergol Immunopathol (Madr) 41(4), 216 (mild / 2 cases) (self-resolving)

(2011): Gross V+, J Crohns Colitis 5(2), 12927%

(2011): Tromm A+, Gastroenterology 140(2), 4253%

(2003): Coghlan D+, Paediatr Drugs 5(10), 685 [REVIEW] (rare)

(2003): Delacourt C+, Respir Med 97, S27

(2001): Reichel W+, Int J Clin Pract 55(2), 100

(2001): Terzano C+, Eur Rev Med Pharmacol Sci 5(1), 17-2

Allergic reactions 

(2000): Bircher AJ+, Dermatology 200(4), 349

(1995): Lepoittevin JP+, Arch Dermatol 131(1), 31-7

(1993): Fedler R+, Hautarzt 44(2), 91-5

Infection 

(2014): Schmelz R+, BMC Gastroenterol 14(1), 19748%

(2010): Thacker D+, Ann Thorac Surg 89 (3), 837

Systemic reactions 

(2012): Davila-Fernandez G+, Allergol Immunopathol (Madr) 40(6), 392

(2012): Salava A+, Contact Dermatitis 67(4), 244



Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of budesonide MMX in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Adverse reactions attributed to entire drug class Corticosteroid / Glucocorticoid

Atrophy / Skin atrophy 

(2020): Niculet E+, Clin Cosmet Investig Dermatol 13, 1041-1050 [REVIEW]

Cushingoid features 

(2016): Matthews E+, Cochrane Database Syst Rev (5), CD003725 [REVIEW]

Hirsutism 

(2016): Matthews E+, Cochrane Database Syst Rev (5), CD003725 [REVIEW]

Behavioral disturbances / personality changes 

(2016): Matthews E+, Cochrane Database Syst Rev (5), CD003725 [REVIEW]

Cognitive impairment 

(2017): Ismail MF+, Future Oncol 13(29), 2719 [REVIEW]

Depression 

(2017): Ismail MF+, Future Oncol 13(29), 2719 [REVIEW]

(2011): Celano CM+, Dialogues Clin Neurosci 13(1), 109 [REVIEW]

Insomnia 

(2017): Ismail MF+, Future Oncol [REVIEW]

Mania 

(2017): Ismail MF+, Future Oncol 13(29), 2719 [REVIEW]

Mood changes 

(2017): Ismail MF+, Future Oncol 13(29), 2719 [REVIEW]

Neurotoxicity 

(2014): Prescrire Int 23(150), 153 (violent behavior)

Psychiatric adverse effect 

(2019): Staub Y+, J Oncol Pharm Pract Oct, Epub ahead of print65–78%Pediatric

Psychosis 

(2021): Huynh G+, J Pharm Technol 37(2), 120-126 [REVIEW] (13 cases)

(2017): Ismail MF+, Future Oncol 13(29), 2719 [REVIEW]

Sleep disturbances 

(2020): Cole JL, Fed Pract 37(6), 260-267 [REVIEW]

Diabetes mellitus 

(2016): Broder MS+, Semin Arthritis Rheum 46(2), 246 [REVIEW]

Hypoglycemia 

(2020): Delfs N+, J Clin Med 9(12), E40794%

Weight gain 

(2016): Matthews E+, Cochrane Database Syst Rev (5), CD003725 [REVIEW]

Gastrointestinal disorder / discomfort 

(2019): Qian G+, Int Urol Nephrol March, Epub ahead of print [REVIEW]

Pancreatitis / acute pancreatitis 

(2010): Lipsker D+, Dermatology 220 (3), 264

(2010): Ouakaa-Kchaou A+, Tunis Med 88 (2)

(2008): Bhavsar B+, JOP 9 (5), 664

(2008): Cagdas DN+, J Cardiovasc Pharmacol Ther 13 (4), 298

(2008): Tsuruoka K+, Nihon Jinzo Gakkai Shi 50 (7), 948

(2007): Fardet L+, Drug Saf 30 (10), 861

(2005): Trivedi CD+, J Clin Gastroenterol 39 (8), 709

(2003): Boruchowicz A+, Gastroenterol Clin Biol 27 (5), 560

Osteonecrosis / avascular necrosis 

(2021): Zgheib NK+, Per Med Aug, Online ahead of print7% (grade 4)Pediatric

Osteoporosis 

(2021): Cho SK+, Endocrinol Metab (Seoul) Jun, Online ahead of print [REVIEW]

(2020): Ward LM, Front Endocrinol (Lausanne) Dec, eCollectionPediatric

Cataract 

(2016): Broder MS+, Semin Arthritis Rheum 46(2), 246 [REVIEW]

(2010): Habot-Wilner Z+, Acta Ophthalmol 88 (8), e299

(2010): Lee SW+, Acta Ophthalmol 88 (8), e344

(2010): Taylor JB+, J Child Neurol 25 (8), 1017

(2010): Thorne JE+, Ophthalmology 117 (7), 1436

(2009): Weatherall M+, Respirology 14 (7), 983

(2008): Nerome Y+, Pediatr Int 50 (4), 541

(2007): James ER, J Ocul Pharmacol Ther 23 (5), 403

(2006): Conti SM+, Curr Opin Ophthalmol 17 (3), 235

(2006): Ernst P+, Eur Respir J 27 (6), 1168

(2006): Gartlehner G+, Ann Fam Med 4 (3), 253

Chorioretinopathy 

(2006): Bouyon A+, Rev Med Interne 27 (6), 487

Endophthalmitis 

(2006): Conti SM+, Curr Opin Ophthalmol 17 (3), 235

Glaucoma 

(2016): Broder MS+, Semin Arthritis Rheum 46(2), 246 [REVIEW]

(2010): Lee SW+, Acta Ophthalmol 88 (8), e344

(2007): El Afrit MA+, J Fr Ophtalmol 30 (1), 49

Pneumonia 

(2016): Broder MS+, Semin Arthritis Rheum 46(2), 246 [REVIEW]

Adverse effects 

(2021): Ma S+, Signal Transduct Target Ther 6(1), 83 [REVIEW] (passim)

(2021): Santiago T+, Rheumatology (Oxford) Jan, Online ahead of print [REVIEW]

(2020): Cheng W+, Front Pharmacol Sep, eCollection [REVIEW] (mild) (passim)

(2020): Sterne JAC+, JAMA Sep, Online ahead of print [REVIEW]

Adverse reactions attributed to entire drug class Corticosteroid, inhaled

Epistaxis (nosebleed) 

(2020): Donaldson AM+, Otolaryngol Head Neck Surg Jun, Online ahead of print [REVIEW]

Adrenal insufficiency 

(2016): Kapadia CR+, JAMA Pediatr 170(2), 163

Fractures 

(2014): Mattishent K+, Drugs 74(5), 539 [REVIEW]

Pneumonia 

(2014): Mattishent K+, Drugs 74(5), 539 [REVIEW]

Adverse effects 

(2020): McDonnell J+, Curr Allergy Asthma Rep 20(11), 69 [REVIEW]

Side effects 

(2015): Matera MG+, Expert Opin Drug Saf 14(4), 533 [REVIEW] (local and systemic)

Page last updated 08/02/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top